Company Performance - Indivior PLC reported quarterly earnings of $0.51 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and up from $0.44 per share a year ago, representing an earnings surprise of +96.15% [1] - The company posted revenues of $302 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 22.05%, compared to revenues of $299 million in the same quarter last year [2] - Over the last four quarters, Indivior has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Indivior shares have increased approximately 40% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $253.66 million, and for the current fiscal year, it is $1.21 on revenues of $1.02 billion [7] Industry Outlook - The Medical - Drugs industry, to which Indivior belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Core Insights - Shake Shack (SHAK) reported quarterly earnings of $0.44 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and showing an increase from $0.27 per share a year ago, resulting in an earnings surprise of +18.92% [1] - The company achieved revenues of $356.47 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.75% and up from $316.5 million year-over-year [2] - Shake Shack's stock has increased approximately 8.6% since the beginning of the year, outperforming the S&P 500's gain of 8.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $364.32 million, and for the current fiscal year, it is $1.36 on revenues of $1.45 billion [7] - The estimate revisions trend for Shake Shack was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Retail - Restaurants industry, to which Shake Shack belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Quanta Services reported quarterly earnings of $2.48 per share, exceeding the Zacks Consensus Estimate of $2.43 per share, and showing an increase from $1.90 per share a year ago [1][2] - The company achieved revenues of $6.77 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.34%, and up from $5.59 billion year-over-year [3] - Quanta Services has consistently outperformed earnings estimates, surpassing consensus EPS estimates in all four of the last quarters [2][3] Earnings Performance - The earnings surprise for the latest quarter was +2.06%, while the previous quarter had a surprise of +7.23% [2] - The current consensus EPS estimate for the upcoming quarter is $3.16, with expected revenues of $7.21 billion, and for the current fiscal year, the EPS estimate is $10.32 on revenues of $27.04 billion [8] Stock Performance - Quanta Services shares have increased by approximately 30.1% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.2% [4] - The stock currently holds a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Outlook - Quanta Services operates within the Zacks Engineering - R and D Services industry, which is currently ranked in the top 35% of over 250 Zacks industries [9] - The industry’s performance can significantly influence the stock's performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

分组1 - TC Energy reported quarterly earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.56 per share, but down from $0.69 per share a year ago, representing an earnings surprise of +5.36% [1] - The company posted revenues of $2.71 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.15%, compared to year-ago revenues of $2.99 billion [2] - Over the last four quarters, TC Energy has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] 分组2 - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.2% [3] - The current consensus EPS estimate for the coming quarter is $0.60 on revenues of $2.65 billion, and for the current fiscal year, it is $2.58 on revenues of $10.65 billion [7] - The Zacks Industry Rank for Alternative Energy - Other is currently in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

CVS Health (CVS) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.47 per share. This compares to earnings of $1.83 per share a year ago. These figures are adjusted for non- recurring items. CVS Health shares have added about 38.8% since the beginning of the year versus the S&P 500's gain of 8.2%. What's Next for CVS Health? While CVS Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? O ...

SNDL Inc. (SNDL) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +125.00%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.04, delivering a surprise of +33.33%. Over the last four quarters, the compa ...

Core Insights - Aurinia Pharmaceuticals reported quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share, but showing significant improvement from $0.02 per share a year ago, resulting in an earnings surprise of -5.88% [1] - The company achieved revenues of $70.01 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 10.41% and up from $57.19 million year-over-year [2] - Aurinia has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Future Outlook - The sustainability of Aurinia's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $64.44 million, and for the current fiscal year, it is $0.59 on revenues of $258.71 million [7] - The estimate revisions trend for Aurinia was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Aurinia belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Xencor, is expected to report a quarterly loss of $0.78 per share, with revenues projected at $20.1 million, reflecting an 18.5% year-over-year increase [9]

Company Performance - Cigna reported quarterly earnings of $7.2 per share, exceeding the Zacks Consensus Estimate of $7.14 per share, and up from $6.72 per share a year ago, representing an earnings surprise of +0.84% [1] - The company posted revenues of $67.13 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 7.09%, compared to revenues of $60.47 billion in the same quarter last year [2] - Over the last four quarters, Cigna has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Cigna shares have increased approximately 7.9% since the beginning of the year, while the S&P 500 has gained 8.2% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $7.93 on revenues of $64.08 billion, and for the current fiscal year, it is $29.68 on revenues of $258.19 billion [7] Industry Context - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cigna's stock performance [5][6]

Company Performance - Integra LifeSciences reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.43 per share, but down from $0.63 per share a year ago, indicating an earnings surprise of +4.65% [1] - The company posted revenues of $415.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.05%, although this represents a decline from year-ago revenues of $418.17 million [2] - Over the last four quarters, Integra has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Integra shares have declined approximately 45.5% since the beginning of the year, contrasting with the S&P 500's gain of 8.2% [3] - The current Zacks Rank for Integra is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $419 million, and for the current fiscal year, it is $2.24 on revenues of $1.67 billion [7] - The outlook for the Medical - Instruments industry, to which Integra belongs, is currently in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8]

Core Insights - Methanex reported quarterly earnings of $0.97 per share, significantly exceeding the Zacks Consensus Estimate of $0.42 per share, and up from $0.62 per share a year ago, representing an earnings surprise of +130.95% [1] - The company posted revenues of $797 million for the quarter ended June 2025, which fell short of the Zacks Consensus Estimate by 8.8% and decreased from $920 million year-over-year [2] - Methanex shares have declined approximately 32.2% year-to-date, contrasting with the S&P 500's gain of 8.3% [3] Earnings Outlook - The future performance of Methanex's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.53 on revenues of $976.2 million, while for the current fiscal year, the estimate is $3.10 on revenues of $4 billion [7] Industry Context - The Chemical - Diversified industry, to which Methanex belongs, is currently ranked in the bottom 5% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Methanex's stock may also be influenced by the overall outlook for the industry, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]